MARC Record from marc_nuls

LEADER: 02882cam 2200433 i 4500
001 9925050390001661
005 20171212121625.0
008 140213t20132013flua b 001 0 eng
010 $a2013013392
016 7 $a101613816$2DNLM
020 $a9781466555464 (hardback : alk. paper)
020 $a1466555467 (hardback : alk. paper)
035 $a(OCoLC)778426503
035 $a(OCoLC)ocn778426503
040 $aDLC$beng$erda$cDLC$dBTCTA$dOCLCO$dYDXCP$dIXA$dCDX$dOCLCF$dNLM
042 $apcc
049 $aCNUM
050 00 $aRS380$b.H37 2013
060 00 $a2013 G-636
060 10 $aQV 778
082 00 $a338.4/76151$223
084 $aBUS076000$aMED071000$2bisacsh
100 1 $aHandfield, Robert B.
245 10 $aPatient-focused network integration in biopharma :$bstrategic imperatives for the years ahead /$cRob Handfield, PhD.
264 1 $aBoca Raton :$bCRC Press, Taylor & Francis Group,$c[2013]
264 4 $c℗♭2013
300 $axiii, 183 pages :$billustrations ;$c24 cm
336 $atext$2rdacontent
337 $aunmediated$2rdamedia
338 $avolume$2rdacarrier
504 $aIncludes bibliographical references and index.
520 $a"Preface This book started out as an interesting set of conversations with some very insightful and intelligent people. For twenty-five years, I've studied supply chains in almost every industry, including oil and gas, automotive, electronics, industrial production, and even financial services. And every time I met with executives, I met with the same statements: "We're different-- you don't understand." But in the end, after spending enough time with these executives, it became clear that the same principles of supply chain management applied. Perhaps a different context, different terminology, but in the end, the same rules applied. When I started dabbling in healthcare, I originally encountered the same sets of objections. "Healthcare is different," I would hear, "After all, you have to consider the patient." But as I spent more and more time with healthcare executives, I only rarely heard the patient mentioned in the discussion. More often than not, the discussion focused on compliance, reimbursement, diagnosis-related groups (DRGs), and other terms that had very little to do with patient care. And as I studied the industry more, it became clear that organizations in the healthcare value chain, from the patient through hospitals, wholesalers, through insurance payers, manufacturers, and finally research and development (R&D), were not very well connected at all"--$cProvided by publisher.
650 0 $aPharmaceutical biotechnology.
650 0 $aPharmaceutical biotechnology industry.
650 0 $aBiological products$xTherapeutic use.
650 0 $aCommunication in pharmacy.
947 $fSHHS$hBOOK$p$69.95$q1
949 $aRS380 .H37 2013$i31786102875660
994 $a92$bCNU